Skip to main content
. 2014 May 8;14:326. doi: 10.1186/1471-2407-14-326

Table 2.

Association with PathCR

Variable PathCR No PathCR Chi-Sq p
ER
 
 
0.833
0.3613
Negative
7 (35.0%)
5 (25.0%)
 
 
Positive
3 (15.0%)
5 (25.0%)
 
 
PR
 
 
5.000
0.0253
Negative
10 (50.0%)
6 (30.0%)
 
 
Positive
0 (0.0%)
4 (20.0%)
 
 
Run-in Treatment
 
 
1.308
0.2528
Nab-paclitaxel
7 (30.4%)
3 (13.1%)
 
 
Trastuzumab 6 (26.1%) 7 (30.4%)